Author

R Pfister

Observed names: Pfister, R., R P Pfister, Romain Pfister

Institutions: University of Cologne, University Hospital Cologne

Observed institutions: University of Cologne, University Hospitals of the Ruhr-University of Bochum, Heart and Diabetes Center North Rhine-Westphalia, University Hospital Cologne

OpenAlex ID: A5125238971

TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation

2023 · Julien Dreyfus, Xavier Galloo, et al. · European Heart Journal · 206

PDF

Auffälligkeit bei 44-jährigem Patienten nach Anlage eines Venenkatheters

2009 · G Michels, R Pfister, et al. · DMW - Deutsche Medizinische Wochenschrift · 2

Variant-specific differences in hereditary transthyretin cardiac amyloidosis

2025 · S A Muller, C Knackstedt, et al. · European Heart Journal · 1

Feasibility and outcomes of pulmonary vein isolation after transcatheter tricuspid valve intervention in patients with atrial fibrillation

2026 · J Schipper, J Woermann, et al. · EP Europace

Transitions in heart failure therapy prior to acoramidis use in transthyretin cardiomyopathy: real world insights from the german starttr cohort

2026 · C Morbach, C Ohlmeier, et al. · European Journal of Heart Failure

A trial emulation study comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy using calibration and indirect treatment comparison methods: the ReplicATTR Study

2026 · P Zwetsloot, P Debonnaire, et al. · European Journal of Heart Failure

Early realworld use of acoramidis insights from the german starTTR cohort

2026 · C Morbach, C Ohlmeier, et al. · European Journal of Heart Failure

Rationale and design of ACO-SWITCH - a phase 4 study evaluating serum transthyretin levels in patients with ATTR-CM who switched from tafamidis to acoramidis

2026 · R Pfister, L Michel, et al. · European Journal of Heart Failure

Design and rationale of DemonsTTRate: a global, long-term observational study to evaluate vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

2026 · P Garcia-Pavia, R Khedraki, et al. · European Journal of Heart Failure

Machbarkeit und Sicherheit von hochintensivem Intervalltraining während einer kardiotoxischen Krebsbehandlung – ENTRANCE – eine Pilotstudie

2026 · N Zoth, A Berling-Ernst, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie

Myosin-Inhibitor-Therapie bei obstruktiver hypertropher Kardiomyopathie mit Mavacamten: Fokussierte Beurteilung des funktionellen Remodelings in der kardialen MRT

2026 · L Pennig, N Beste, et al. · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren

Three-dimensional echocardiography-derived right ventricular forward stroke volume to end-systolic volume index in tricuspid valve transcatheter edge-to-edge repair

2026 · C Iliadis, P Von Stein, et al. · European Heart Journal Supplements

Efficacy and Safety of TricValve Bicaval Implantation in patients with Pacemakers

2025 · L Dominguez Rodriguez, A Sanchez Recalde, et al. · European Heart Journal

Right ventricular to pulmonary artery coupling and clinical outcomes after interatrial shunting in heart failure

2025 · J B Bartunek, B K Kilicaslan, et al. · European Heart Journal

Benefits of tricuspid valve intervention on outcomes based on underlying etiology in patients with severe functional tricuspid regurgitation: insights from the international TRIGISTRY

2025 · C Iliadis, J Dreyfus, et al. · European Heart Journal

Haemodynamic effect of transcatheter tricuspid valve annuloplasty and its association with clinical outcomes

2025 · C Iliadis, A Kalkan, et al. · European Heart Journal

Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy

2025 · K Seuthe, A Feidakis, et al. · European Heart Journal

Comprehensive cardiovascular magnetic resonance for evaluating structural myocardial changes in patients with hypertrophic obstructive cardiomyopathy treated with the first myosin inhibitor

2025 · K Seuthe, R Pfister, et al. · European Heart Journal

When to stop? Real-world decision pathways for transthyretin stabilizer discontinuation in cardiac amyloidosis

2025 · K Knoll, D Lavall, et al. · European Heart Journal

Real-world insights into treatment modalities and emerging myosin inhibitor therapy for hypertrophic obstructive cardiomyopathy: early findings from the German REDUCE-Registry

2025 · K Seuthe, A Feidakis, et al. · European Heart Journal

Prospective evaluation of cardiac safety in breast cancer patients after adjuvant treatment with epirubicin, cyclophosphamide, doxetaxel and with or without trastuzumab: A single center experience

2015 · J Puppe, D van Ooyen, et al. · Geburtshilfe und Frauenheilkunde

Works count: 26

Citation count: 209

H-index: 2

I10-index: 1